Cytochroma to present at upcoming investor conferences

MARKHAM, ON, Sept. 7, 2011 /CNW/ - Cytochroma today announced that the Company will be presenting a corporate overview at the following investor conferences:

  • Charles W. Bishop, Cytochroma's President and Chief Executive Officer will be presenting at the Stifel Nicolaus Healthcare Conference 2011 at 4:25 PM ET on Wednesday, September 7, 2011 at the Four Seasons Hotel in Boston.
  • Eric J. Messner, Cytochroma's Chief Operating Officer will be presenting at the RW Baird 2011 Health Care Conference at 1:45 PM ET on Thursday, September 8, 2011 at The New York Palace Hotel in New York City.

About Cytochroma

Cytochroma is a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary products to treat and prevent the clinical consequences of vitamin D insufficiency and secondary hyperparathyroidism associated with chronic kidney disease (CKD).  The Company specializes in developing new therapies which are designed to safely and effectively treat patients with stage 3, 4 or 5 CKD.  Cytochroma also has a portfolio of CYP24 and phosphate-uptake inhibitors in early stage development.

For more information about Cytochroma, please visit

SOURCE Cytochroma

For further information:

Cytochroma Investors:
Gordon Ngan
Executive Director, Corporate Development
Tel: +1 (905) 479-5306 ext. 333

Cytochroma Media:
Robert Stanislaro (Financial Dynamics)
Tel: +1 (212) 850-5657

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890